ArticleHepatitis monthly2011
Post-transfusion occult hepatitis B (OBI): a global challenge for blood recipients and health authorities.
Article in Hepatitis monthly, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Prevalence of hepatitis B infection in the Gambian population: A narrative review of recent developments.Preventive medicine reports · 2023Review
- Occult Hepatitis B Virus Infection among β-Thalassemia Major Patients in Ahvaz City, Iran.The American journal of tropical medicine and hygiene · 2021Article
- Characteristics of escape mutations from occult hepatitis B virus infected patients with hematological malignancies in South Egypt.World journal of hepatology · 2017Article
- Molecular Characterization of Pre-Core/Core and S Region of Hepatitis B Virus in Hemodialysis Patients With Occult Hepatitis B Infection.Jundishapur journal of microbiology · 2015Article
- Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions.World journal of gastroenterology · 2014Review
- Intensity of HLA-A2 Expression Significantly Decreased in Occult Hepatitis B Infection.Jundishapur journal of microbiology · 2014Article
- Review
- Epidemiology of occult hepatitis B infection among thalassemic, hemophilia, and hemodialysis patients.Hepatitis monthly · 2012Article
- Nucleic acid testing for the detection of HBV DNA.Hepatitis monthly · 2011Article
- Overproduction of CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 in β-thalassemia major or patients.Annals of Saudi medicineArticle
- New horizons for reduction of blood use: Patient blood management.Asian journal of transfusion scienceReview
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B is one of the most frequent post-transfusion infections. Occult hepatitis B infection (OBI) is a form of hepatitis B infection in which, despite the presence of HBV-DNA in the serum and hepatocytes of the carrier, HBsAg is absent. In addition to the risk of transmission through the transfusion of infected blood, reactivation of hepatitis B in OBI patients and recipients of their blood can lead to cirrhosis, hepatic cancer, and reactivation of viral replication in the carrier. Therefore, effective assays to assess and screen for OBI in blood donors are of paramount importance and require urgent attention. Recently, several investigations in various regions of Iran have reported OBI in blood donors. In response, there has been a drive to apply more specific, sensitive, and accurate methods for the detection of HBV, which should become an obligatory screening process for all blood transfusion services. In this review, we address the progression of occult hepatitis B and the common problems associated with occult hepatitis B worldwide. Finally, we reflect on the research and screening that is being performed in Iran to deal with this problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.